Use of Oxygen in Heart Failure With Preserved Ejection Fraction

Heart Failure Clinical Trial

— STOP-EF  

Official title:

Randomised, Cross Over, Single Blind, Control Trial of Short Term Oxygen Use During Cycle Ergometry in Patients With Chronic Heart Failure With Preserved Ejection Fraction

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02949531
• Other study ID #: R1965
• Status: Completed
• Phase: Phase 2
• Start date: November 3, 2016
• Est. completion date: February 15, 2017

Study information

• Verified date: September 2016
• Source: Hull and East Yorkshire Hospitals NHS Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Oxygen is routinely given to patients with common conditions such as COPD and heart failure. There is no evidence behind giving oxygen to patients specifically in heart failure due to a stiff heart.

This study aims to explore the effect oxygen has on the ability of patients with chronic heart failure and the ability to exercise. Other common variables will be assessed such as heart rate and blood pressure to observe the response to varying concentrations of oxygen.

The concentrations chosen are commonly offered in hospitals and indeed are being delivered through standard equipment found in all hospitals in the country.

It is hoped that studying the effect of short term oxygen on patients with heart failure will help to identify the effectiveness of oxygen in longer term therapy for patients who are often breathless with a decreased exercise tolerance.

Description:

Many patients with reduced exercise tolerance have a preserved left ventricular function. These patients are labelled as having heart failure with preserved ejection fraction (HeFPEF), when the combined use of echocardiography and biochemistry. The prevalence and the incidence of HeFPEF are on the increase and currently it accounts for around 50% of all patients diagnosed with HF. The last twenty years of research has led to great improvement in available treatments for heart failure with reduced ejection fraction (HeFREF); however, current guidelines only suggest diuretics to improve symptoms of those patients with HeFPEF: clinical trials of several pharmacological interventions have failed to show convincing reductions in morbidity or mortality for patients with HeFPEF.

The effect of oxygen therapy on exercise capacity has remained poorly understood in HeFREF and, at the time of writing this study, it has never been explored in HeFPEF. The investigators recently completed a study showing an increase in exercise time, exercise load at peak exercise and peak metabolic equivalent on cycle ergometry with 28% oxygen supplementation and further increments when 40% oxygen supplementation was used in patients with heart failure with reduced ejection fraction.

The investigators aim to improve exercise time in patients with HeFPEF with oxygen supplementation. Identifying the correct dose of oxygen will be a further aim to avoid hyperoxygenation but provide adequate oxygen to improve exercise tolerance.

Patients will be identified from heart failure clinics and will be invited for screening visit. Eligible patients will have three treatment visit at least one week apart (each visit with a different oxygen concentration i.e room air, 28% and 40% oxygen, randomly determined by sealed envelopes)

Patients will use standard cycle ergometry to exercise and work load will be increased every minute by 5-10 watts. Patients will be encouraged to cycle until tired. At the end of cycling, exercise time, peak metabolic equivalent, work load, shortness of breath score will be noted at each visit.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: February 15, 2017
• Est. primary completion date: February 15, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Over 50 years of age and able and willing to give consent

• Have signs and/or symptoms of heart failure

• Left ventricular ejection fraction > 45%

• NT-pro BNP > 220 pg/ml (in the previous 12 months)

• On any diuretic

Exclusion Criteria:

• Unable or unwilling to give consent

• Recent (<1 month) acute myocardial infarct or cerebrovascular event

• Significant renal dysfunction (eGFR <30 ml.min-1.1.73m-2)

• Significant anaemia (Haemoglobin < 100 g.L-1)

• Systolic blood pressure <90 mmHg, or >180 mmHg

• Severe mitral or aortic valve disease

• Diagnosis of severe chronic lung disease

• Involvement in another medicinal trial within the past four weeks

• Unable to use cycle

• Any planned admission in the following 3-4 weeks (patient can be reconsidered for enrolment after planned admission)

Related Conditions & MeSH terms

• Heart Failure

Intervention

Drug:
• oxygen

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Hull and East Yorkshire Hospitals NHS Trust

References & Publications (1)

Shah P, Pellicori P, Rimmer S, Rigby AS, Clark AL. Effect of increased inspired oxygen on exercise performance in patients with heart failure and normal ejection fraction. Int J Cardiol. 2018 Oct 1;268:166-169. doi: 10.1016/j.ijcard.2018.05.029. Epub 2018 May 24. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change in exercise time with the use of 21%, 28% and 40% oxygen	the total time cycled in each arm	at 3 weeks
Secondary	change in shortness of breath with the use of 21%, 28% and 40% oxygen	shortness of breath measured using BORG score	at 3 weeks
Secondary	change in Peak metabolic equivalent with the use of 21%, 28% and 40% oxygen	measured using standard peak metabolic equivalent	at 3 weeks

External Links

•   Publication Link